Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2022-03-17 Regulatory Filings
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby enclose a copy of Investor Relations Presentation for March 2022 ....
Regulatory Filings
2022-03-17 English
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be attending ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchange about the schedule of an analyst/institutional investor meeting at a virtual investor conference. It references compliance with SEBI Listing Obligations and Disclosure Requirements, and explicitly states that no unpublished price sensitive information will be discussed. The document does not contain any financial data, detailed financial results, or report content. It is an announcement of an upcoming investor presentation event rather than the presentation itself or a financial report. The document length is only 1671 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Investor Presentation (IP) as it relates to investor meetings and presentations, but since this is only an intimation of the schedule and not the presentation content itself, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about investor meetings under SEBI regulations.
2022-03-04 English
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby enclose a copy of Investor Relations Presentation for February ....
Regulatory Filings
2022-02-25 English
We hereby enclose the Transcript of Earnings conference call held on Wednesday, February 16, 2022 regarding the financial performance of the Company for the quarter and nine months ended ....
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call held on February 16, 2022, discussing the financial performance of Fermenta Biotech Limited for the quarter and nine months ended December 31, 2021. It includes operational highlights, financial results, management commentary, and a Q&A session with analysts. The presence of management discussion, financial figures, and Q&A indicates this is a full transcript of an earnings call rather than a brief earnings release or a summary. The document references the quarter and nine months financial results, consistent with an earnings call transcript. Therefore, the appropriate classification is Call Transcript (CT).
2022-02-22 English
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation given ....
Regulatory Filings
2022-02-17 English
Intimation of Earnings Presentation for 9 Months / Quarter 3 - Financial Year 2021-2022 Further to our intimation dated February 14, 2022, regarding approval of un-audited Financial Results ....
Investor Presentation Classification · 95% confidence The document is titled 'Earnings Presentation for 9 Months / Quarter 3 – Financial Year 2021-2022 [9M/Q3 – FY22]' and contains detailed financial data including standalone and consolidated quarterly and year-to-date financial performance, operational highlights, revenue mix, and other financial metrics. It is an earnings presentation document as indicated by the title and content. The document is about 15,000 characters long, which is substantial and contains actual financial data and analysis, not just an announcement or a brief summary. Therefore, it fits the category of an Investor Presentation (IP) rather than a simple Earnings Release (ER) which typically contains only key highlights. The presence of detailed charts, operational highlights, and company overview further supports classification as an Investor Presentation.
2022-02-15 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.